Tenacia Therapeutics News

Tenacia, Rapport Strike $308M China Epilepsy Deal

March 9, 2026

Tenacia Therapeutics inks a deal worth up to 308 million USD for China rights to Rapport’s experimental epilepsy drug, extending Western CNS innovation into the China market.